RARA CRAFT DATABASE for FDA Medical Devices
510(k)K262294

FDA DEVICE FACTS

dS FootAnkle 16Ch 1.5T;dS FootAnkle 16Ch 3.0T;dS HiRes Hand/Wrist 16Ch 1.5T;dS HiRes Hand/Wrist 16CH 3.0T;dS Small Extremity 16Ch 1.5T;dS Small Extremity 16Ch 3.0T

Philips Medical Systems Nederland B.V.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEJuly 24, 2026PRODUCT CODEMOS

Indications for use

dS FootAnkle 16Ch 1.5T and 3.0T: The dS FootAnkle 16Ch 1.5T and 3.0T MR Coils are intended to be used in conjunction with Philips 1.5T/3.0T Magnetic Resonance Scanners to produce diagnostic images of the foot and ankle anatomy in adolescent and adult patients that can be interpreted by a trained physician. dS HiRes Hand/Wrist 16Ch 1.5T and 3.0T: The dS HiRes Hand/Wrist 16Ch 1.5T and 3.0T MR Coils are intended to be used in conjunction with Philips 1.5T/3.0T Magnetic Resonance Scanners to produce diagnostic im ages of the hand and wrist anatomy in adolescent and adult patients that can be interpreted by a trained physician. dS Small Extremity 16Ch 1.5T and 3.0T: The dS Small Extremity 16Ch 1.5T and 3.0T MR Coils are intended to be used in conjunction with Philips 1.5T/3.0T Magnetic Resonance Scanners to produce diagnostic images of the small extremities anatomy in neonate, infant, children, adolescent and adult patients that can be interpreted by a trained physician. The Indications for Use statements for the subject devices dS FootAnkle 16Ch 1.5T, dS FootAnkle 16Ch 3.0T, dS HiRes Hand/Wrist 16Ch 1.5T, dS HiRes Hand/Wrist 16Ch 3.0T, dS Small Extremity 16Ch 1.5T and dS Small Extremity 16Ch 3.0T are not identical to those of the predicate devices . However, the differences do not alter the intended diagnostic use of the devices, nor do they affect the safety and effectiveness of the devices relative to the predicate devices. Both the subject and predicate devices have the same intended use, namely, to be used in conjunction with a MR Scanner to produce diagnostic images of the anatomy of interest that can be interpreted by a trained physician. Design Features/Fundamental Scientific Technology Magnetic resonance imaging using receive ‑only radiofrequency (RF) coils is the technological principle for both the subject and predicate devices. This principle is based on the use of dedicated RF coil elements to receive magnetic resonance signals generated in hydrogen nuclei within the human b ody during MRI examinations, which are subsequently processed by the MRI system to generate diagnostic images. At a high level, the subject and predicate devices are based on the same technological elements, including:  Receive‑only phased array RF coil el ements used in conjunction with an MRI system body coil for RF transmission,  Use with compatible 1.5T and/or 3.0T MR systems,  Acquisition of MR signals for diagnostic imaging of anatomy (Foot/ankle, Hand/wrist and Small extremities),  Coil housings and pads designed to allow positioning and stabilization of the anatomy,  Use of the MR system for signal processing and image reconstruction. The following technological differences exist between the subject and predicate devices:  Limited material changes to non‑active components and supplier changes,  The IFU of the subject devices have been updated to improve clarity, alignment with current clinical use, and consistency with applicable Philips MR System documentation . In addition, Warnings clarified and updated based on current coil specific risk profile. These differences do not alter the fundamental scientific technology of the devices and do not raise new questions of safety or effectiveness relative to the predicate devices. Summary of Non‑Clinical Performance Data Non-clinical verification and validation test ing was performed with re spect to the intended use, the technical claims, the design requirements and risk management activities for the subject devices. The verification and validation results demonstrate that the subject devices meet the acceptance criteria and are adequate for their intended use. Biocompatibility evaluation was conducted for the subjec t devices in accordance with FDA recognized consensus standards for the biological evaluation of medical devices. The assessment considered the nature and duration of patient contact of the subject devices. Testing included, as appropriate Cytotoxicity, Sensitization and Irritation. The results of the biocompatibility evaluation demonstrated that the materia ls used in the subject devices are biocompatible for their intended patient contact and duration of use. Risk management activities were performed to evaluate hazards associated with the design changes. The evaluation demonstrated that identified risks are adequately controlled and that no new risks are introduced, and that the overall residual risks are acceptable. The non-clinical performance data summarized above demonstrate that the subject devices perform as intended and support a determination of substantially equivalence to the legally marketed predicate devices in terms of safety and effectiveness. Summary of Clinical Data Clinical testing was not required to support the determination of substantial equivalence because the indications for use of the subject devices remain similar to those of the predicate devices and the technological differences do not raise different questions of safety or effectiveness.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 11, 2026